Please assess the completion status of the following clinical trial:

Trial Title: Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women at 28-32 weeks of gestation~* both HBsAg and HBeAg positive~* good compliance~Exclusion Criteria:~* Coinfection of HAV, HCV, HEV, HIV, and STD~* With history of antiviral treatment against HBV~* With chronic disease, such as heart and kidney disease, asthma, diabetes, hyperthyroidism, severe anemia, bleeding disease, autoimmune diseases~* With threatened miscarriage or relevant treatment during the pregnancy~* With pregnant complications such as pregnancy hypertension, preeclampsia, etc~* With history of fetal deformity, or fetal deformity detected by ultrasound examination~* With ALT \>10 times upper limit, or total bilirubin \>3 times upper limit, of normal value

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Telbivudine (Type: EXPERIMENTAL): HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
- Control (Type: NO_INTERVENTION): Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).